2-[羧甲基-[2-(羧甲基氨基)-2-羟基乙基]氨基]乙酸 | 33872-70-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-[羧甲基-[2-(羧甲基氨基)-2-羟基乙基]氨基]乙酸
• 英文名称: N-(Carboxymethyl)-N-[2-[(carboxymethyl)amino]-2-hydroxyethyl]glycine
• 英文别名: 2-[[2-[bis(carboxymethyl)amino]-1-hydroxyethyl]amino]acetic acid
• CAS: 33872-70-7
• 化学式: C₈H₁₄N₂O₇
• 分子量: 250.21
• InChiKey: FSRYXNMJLCNZSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.5
• 重原子数：
  17
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  147
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY
  申请人：Technische Universität München

  公开号：EP3494999A1

  公开（公告）日：2019-06-12

  The present disclosure relates to imaging and endoradiotherapy of diseases involving prostate-specific membrane antigen (PSMA). Provided are compounds which bind or inhibit PSMA and furthermore carry at least one moiety which is amenable to radiolabeling. Provided are also medical uses of such compounds.

  本公开涉及涉及前列腺特异性膜抗原（PSMA）相关疾病的成像和内放射治疗。提供了结合或抑制PSMA并且携带至少一个适合于放射标记的基团的化合物。还提供了这类化合物的医疗用途。
• GLYCOSYLATED PSMA INHIBITORS FOR IMAGING AND ENDORADIOTHERAPY
  申请人：Technische Universität München

  公开号：EP3494998A1

  公开（公告）日：2019-06-12

  The present disclosure relates to imaging and endoradiotherapy of diseases involving prostate-specific membrane antigen (PSMA). Provided are compounds which bind or inhibit PSMA and furthermore carry at least one moiety which is amenable to radiolabeling. Provided are also medical uses of such compounds.

  本公开涉及涉及前列腺特异性膜抗原（PSMA）相关疾病的成像和内放射治疗。提供了结合或抑制PSMA并且携带至少一个适合于放射标记的基团的化合物。还提供了这类化合物的医学用途。
• [EN] PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY<br/>[FR] LIGANDS DE PSMA POUR L'IMAGERIE ET L'ENDORADIOTHÉRAPIE
  申请人：UNIV MUENCHEN TECH

  公开号：WO2019115547A1

  公开（公告）日：2019-06-20

  The present disclosure relates to imaging and endoradiotherapy of diseases involving prostate-specific membrane antigen (PSMA). Provided are compounds which bind or inhibit PSMA and furthermore carry at least one moiety which is amenable to radiolabeling. Provided are also medical uses of such compounds.

  本公开涉及涉及前列腺特异性膜抗原（PSMA）相关疾病的成像和内放射治疗。提供了结合或抑制PSMA并且携带至少一个适合于放射标记的基团的化合物。还提供了这类化合物的医疗用途。
• Novel 2-substituted methyl penam derivatives
  申请人：Udayampalayam Palanisamy Senthilkumar

  公开号：US20080015156A1

  公开（公告）日：2008-01-17

  Novel 2-substituted methyl penam derivatives include the formula (I), their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their solvates, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them; wherein A=C or N; Het is a three- to seven-membered heterocyclic ring; R 1 represents carboxylate anion, or —COOR 4 where R 4 represents hydrogen, carboxylic acid protecting group or a pharmaceutically acceptable salt; R 2 and R 3 may be same or different and independently represent hydrogen, halogen, amino, alkyl, protected amino, optionally substituted alkyl, alkenyl, alkynyl and the like; R represents substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heterocyclylalkyl.

  新型2-取代甲基青霉素衍生物包括式(I)，它们的类似物，其互变异构体，其立体异构体，其多晶形式，其溶剂合物，其药学上可接受的盐，以及含有它们的药物组合物；其中A=C或N；Het是一个三至七元杂环环；R1代表羧酸根离子，或—COOR4，其中R4代表氢，羧酸保护基或药学上可接受的盐；R2和R3可以相同也可以不同，并且独立地代表氢，卤素，氨基，烷基，受保护的氨基，可选择地取代的烷基，烯基，炔基等；R代表取代或未取代的烷基，烯基，芳基，芳基烷基，环烷基，杂环基或杂环烷基。
• [EN] ALKYL HALIDES CONVERSION INTO ACYCLIC C3-C6 OLEFINS<br/>[FR] CONVERSION D'HALOGÉNURES D'ALKYLE EN OLÉFINES ACYCLIQUES EN C3-C6
  申请人：TOTAL SE

  公开号：WO2021099539A1

  公开（公告）日：2021-05-27

  The present disclosure relates to a process for converting one or more alkyl halides to acyclic C3-C6 olefins, said process comprising the steps of (a) providing a feedstream comprising one or more alkyl halides; (b) providing a catalyst composition; and (c) contacting said feedstream with said catalyst composition under reaction conditions. The process is remarkable in that said process further comprises a step of steaming said catalyst composition before the step (c) and in that said catalyst composition comprises one or more zeolites and a binder, wherein said one or more zeolites comprise at least one 10-membered ring channel. The present disclosure further relates to the use of a catalyst composition in said process, said catalyst composition comprising one or more zeolites and a binder, wherein said catalyst composition is steamed before use.

  本公开涉及一种将一个或多个烷基卤化物转化为无环C3-C6烯烃的方法，该方法包括以下步骤：(a)提供包含一个或多个烷基卤化物的进料流；(b)提供催化剂组合物；以及(c)在反应条件下将所述进料流与所述催化剂组合物接触。该方法的显著之处在于该方法进一步包括在步骤(c)之前对所述催化剂组合物进行蒸汽处理的步骤，并且所述催化剂组合物包括一个或多个沸石和一个粘结剂，其中所述一个或多个沸石包括至少一个10环通道。本公开还涉及在所述方法中使用催化剂组合物，所述催化剂组合物包括一个或多个沸石和一个粘结剂，其中所述催化剂组合物在使用前进行蒸汽处理。